Study wrapper · #964
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Bailey CJ, Flatt PR, Conlon JM Peptides. 2026.
DOI: 10.1016/j.peptides.2026.171480PubMed: 41747885
Editor's note
This narrative review surveys the pharmacology and clinical development of long-acting amylin analogues, with cagrilintide and CagriSema as central examples alongside newer agents. It notes that gastrointestinal side effects are common during initiation but mostly resolve with continued use. As an expert overview it provides strong context on tracked peptides, though it synthesizes rather than generates primary data.
Plain-language abstract
A review of long-acting amylin analogues describes how agents like cagrilintide, and its combination with semaglutide (CagriSema), are advancing as treatments for obesity and type 2 diabetes.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026